"Identification of Nafamostat and VR23 as COVID-19 drug candidates by targeting 3CL^pro and PL^pro."

ABSTRACT: The sudden increase in the COVID-19 epidemic affected by novel coronavirus 2019 has jeopardized public health worldwide. Hence the necessities of a drug or therapeutic agent that heal SARS-CoV-2 infections are essential requirements. The viral genome encodes a large Polyprotein, further processed by the main protease/ 3C-like protease (3CL^pro) and papain-like proteases (PL^pro) into 16 nonstructural proteins to form a viral replication complex. These essential functions of 3CL^pro and PL^pro in virus duplication make these proteases a promising target for discovering potential therapeutic candidates and possible treatment for SARS-CoV-2 infection. This study aimed to screen a unique set of protease inhibitors library against 3CL^pro and PL

SUBMITTER: Bhowmik D 

PROVIDER: S-EPMC7884051 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature